BMEA - Biomea Fusion Inc logo

Biomea Fusion Inc

BMEA

Biomea Fusion develops oral drugs targeting diabetes and obesity. Its lead candidates, icovamenib and BMF-650, are in clinical trials aimed at restoring insulin production and managing weight, addressing significant metabolic health challenges.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$53today

Score Overview

1 Year
Scoreโ€”
Net Growth60.82%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth41.26%
Net Trend40%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth41.26%
Net Trend40%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Biomea Fusion Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. BMEA does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 0.58โ€”
1 Year2025-10-22
$ 1.44-59.38%
5 Years2021-10-22
$ 10.99-94.68%
All Time2021-04-16
$ 18.60-96.85%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 24M$ 34M
2025$ 0.00-$ 61M$ 55M
2024$ 0.00-$ 138M$ 58M
2023$ 0.00-$ 117M$ 176M
2022$ 0.00-$ 80M$ 113M
IPO2021$ 0.00-$ 41M$ 173M
BMEA - Biomea Fusion Inc logo

Biomea Fusion Inc fundamental performance

Across Biomea Fusion Inc's full reported history, from 2021 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 41M to -$ 61M. Revenue increased in 0% of the years measured; net income in 40%.

Membership

Explore BMEA with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies